Chicago Daily Law Bulletin Dec. 5, 2013
In her column, Professor Doris Estelle Long examines the new world of “biologics,” the chemically synthesized drugs that many pharmaceutical companies believe will carry them through the new “patent cliff” as more and more patents expire.
